-+ 0.00%
-+ 0.00%
-+ 0.00%

Climb Bio reports 70% Gd-IgA1 reduction with CLYM116 in Phase 1 trials

PUBT·10/23/2026 20:03:15
Climb Bio reports 70% Gd-IgA1 reduction with CLYM116 in Phase 1 trials
  • Climb Bio and Mabworks presented Phase 1 results for IgA nephropathy candidate CLYM116/MIL116 at ASN Kidney Week 2026.
  • Healthy volunteer studies showed sustained APRIL suppression and reductions in disease-related biomarkers, supporting dosing every 12 weeks.
  • The drug was generally well tolerated, with no dose-limiting toxicities or treatment-related serious adverse events.
  • The NAVIGATE-2 Phase 2 trial is enrolling patients, with initial data expected in the first half of 2027.
  • A global Phase 3 trial is expected to begin in 2027, pending regulatory feedback.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231601PRIMZONEFULLFEED9852328) on October 23, 2026, and is solely responsible for the information contained therein.